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Summary Background. Pancreatic neuroendocrine tumors
(NETs) are rare but are frequently diagnosed at advanced
stages and require systemic therapy. Patients and methods.
This multicenter, open-label, phase II study evaluated suniti-
nib in Japanese patients with well-differentiated pancreatic
NET. Patients received sunitinib 37.5 mg/day on a continuous
daily dosing (CDD) schedule. The primary endpoint was
clinical benefit rate (CBR; percentage of complete responses
[CRs] plus partial responses [PRs] plus stable disease
[SD] ≥24 weeks). Secondary endpoints included objective
response rate (ORR), tumor shrinkage, progression-free sur-
vival (PFS) probability, safety, pharmacokinetics, and
biomarkers. Results. Twelve patients received treatment. The
CBR was 75 % (95 % confidence interval [CI], 43–94) and
included 6 patients with a PR and 3 with SD. The ORR was
50 % (95 % CI, 21–79). PFS probability was 91 % (95 % CI,
54–99) at 6 months and 71 % (95 % CI, 34–90) at 12 months.
Commonly reported treatment-emergent (all-causality), any-
grade adverse events included diarrhea (n010), hand–foot syn-
drome and hypertension (both n08), fatigue and headache (both
n07), and neutropenia (n06). No deaths on studywere reported;
one death due to disease progression occurred >28 days after end
of treatment. Sunitinib on a CDD schedule resulted in sustained
drug concentrations without accumulation across cycles. Tumor
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responses in all 12 patients did not appear to correlate with
decreases in chromogranin A levels. Conclusions. Sunitinib
37.5 mg/day on a CDD schedule demonstrated antitumor activ-
ity in Japanese patients with unresectable, well-differentiated
pancreatic NET. Commonly reported adverse events were con-
sistent with the known safety profile of sunitinib.
Keywords Efficacy . Japanese . Pancreatic neuroendocrine
tumor . Pharmacokinetics . Phase II . Sunitinib
Introduction
Pancreatic neuroendocrine tumors (NETs) are rare malignan-
cies with a prevalence of 2.23 per 100,000 population in Japan
[1]. The incidence rate of pancreatic NET per year in Japan
(1.01 per 100,000 population) appears higher than in Western
countries (0.32/100,000 in the overall US population and 0.25
in Asian Americans [2]). Surgery, if feasible, is the optimal
treatment approach [3]. However, the majority of patients pres-
ent with unresectable disease. When the current study was
initiated, treatment options available for symptomatic patients
with unresectable disease included somatostatin analogs (e.g.
octreotide, alone or in combination with interferon-alpha) and
the alkylating agent streptozocin (alone or in combination with
doxorubicin), both of which have limited efficacy in patients
with advanced disease [4–6]. Subsequently, targeted anti-
cancer agents have been shown to improve progression-free
survival (PFS) compared with placebo in phase III studies that
included primarily Caucasian patients with advanced pancreatic
NET [7–9].
Vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) are key drivers of angiogenesis
in pancreatic NETs [10, 11]. Sunitinib malate (SUTENT®), an
oral multitargeted inhibitor of numerous receptor tyrosine
kinases including VEGF receptors and PDGF receptors
[12–14], has been shown to delay tumor growth in a RIP1-
Tag2 transgenic mouse model of pancreatic islet-cell tumors
[15, 16]. In a phase II trial, sunitinib demonstrated antitumor
activity in patients with pancreatic NET [17], and in a subse-
quent phase III trial, oral sunitinib 37.5 mg/day on a contin-
uous daily dosing (CDD) schedule prolonged median PFS
relative to placebo in Caucasian and Asian patients with
locally advanced and/or metastatic, well-differentiated pancre-
atic NET [7]. Sunitinib was also associated with a greater
objective tumor response rate than placebo. In an updated
analysis, median overall survival (OS) favored sunitinib (haz-
ard ratio [HR] 0.71, 95 % confidence interval [CI]: 0.47–1.09;
P00.11), despite crossover to sunitinib for most of the patients
randomized to placebo, although statistical significance was
not reached [18]. On the basis of these findings, sunitinib has
been approved multinationally for the treatment of patients
with unresectable or metastatic, well-differentiated pancreatic
NET with disease progression.
We carried out a phase II, open-label, multicenter trial
(NCT01121562) to evaluate the clinical benefit rate (CBR)
of sunitinib in Japanese patients with pancreatic NET. The
sunitinib dose investigated was 37.5 mg/day on the CDD
schedule, which was the same regimen used in a Western
phase III study [7]. Secondary objectives were to assess
objective response rate (ORR) and PFS, to evaluate safety
and tolerability, and to determine the pharmacokinetic (PK)
profile of sunitinib in this patient population.
Patients and methods
Study population
Japanese patients ≥20 years old with histologically or cyto-
logically proven, well-differentiated pancreatic NET (accord-
ing to the World Health Organization 2004 classification [19])
and progressive unresectable advanced or metastatic disease
were eligible to participate. Inclusion criteria comprised docu-
mented evidence of disease progression within 12 months of
study start (by computed tomography [CT] or magnetic reso-
nance imaging [MRI]), and disease not amenable to surgery,
radiation, or combined modality therapy with curative intent.
At least one measurable target lesion according to Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.0
[20] was required, along with adequate organ function, an
Eastern Cooperative Oncology Group performance status
(ECOG PS) of 0 or 1, and a life expectancy of at least
3 months. Patients were excluded if they had poorly differen-
tiated tumors, prior treatment with any tyrosine kinase or anti-
VEGF angiogenic inhibitors, brain metastases, cardiovascular
disease ≤12 months prior to study start, uncontrolled hyper-
tension, an uncontrolled thyroid abnormality, ongoing cardiac
dysrhythmias with medical intervention or a prolonged QT
interval corrected for heart rate (QTc), symptomatic brain
metastases, or a left ventricular ejection fraction of ≤50 %.
Study design and treatment
In this multicenter, open-label, phase II study, all patients
received oral sunitinib37.5 mg/day on a CDD schedule, and
each treatment cycle lasted 28 days. Patients were monitored
for toxicity, and dose reductions to 25 mg/day were permitted
based on individual tolerability. The sunitinib dose could also
be increased to 50 mg/day (if no response was observed in the
first 8 weeks and if individual tolerability permitted). The
primary endpoint was CBR, defined as the proportion of
patients with a confirmed complete response (CR) or partial
response (PR) or stable disease (SD) for ≥24 weeks. CBR was
selected as the primary endpoint because maintaining
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prolonged SD over about half of a year (24 weeks) was
deemed beneficial and clinically meaningful for patients with
pancreatic NET, based on the median PFS of 5.5 months
reported for placebo treatment in a previous global, pivotal,
phase III study [7]. Secondary efficacy endpoints included
ORR, defined as the proportion of patients with a confirmed
CR or PR; tumor shrinkage, defined as the percentage change
from baseline in the sum of the longest diameter of target
lesions; PFS; safety; and PK.
The study was conducted in accordance with the
International Conference on Harmonization Good Clinical
Practice guidelines, the Declaration of Helsinki, and applica-
ble local regulatory requirements and laws. Approval from the
institutional review board or independent ethics committee of
each participating center was required, and written informed
consent was obtained from all patients before screening.
Study assessments
Investigator-assessed tumor imaging by CT, spiral CT, orMRI
was performed at screening and weeks 5 and 9, and then at 8-
week intervals during the study. Additional scans were per-
formed when disease progression was suspected or to confirm
a CR or PR based on RECIST. Safety was assessed at regular
intervals by physical examination and analysis of adverse
events (AEs), laboratory abnormalities (hematology and
blood chemistry), vital signs, 12-lead electrocardiograms
(ECGs), and ECOG PS. AEs were graded using National
Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0. QTc intervals were determined using 12-
lead ECGs in triplicate at baseline, on day 1 of cycles 2 and 3,
every 8 weeks thereafter, and as clinically indicated.
Blood samples were collected before dosing on day 15 (±1)
of cycle 1 and on day 1 of cycles 2–4 to evaluate trough
concentrations (Ctrough) of sunitinib and its active metabolite
SU12662 using a validated high- performance liquid chroma-
tography−tandem mass spectrometry method (Bioanalytical
Systems Inc., West Lafayette, Indiana, USA). An exploratory
analysis investigated potential differences in steady-state
Ctrough values of sunitinib, SU12662, and total drug (sunitinib
plus SU12662) in Japanese versus non-Japanese patient pop-
ulations and in patients with different tumor types. Ctrough
from this Japanese study, a Western pancreatic NET trial
[15], and from studies of Japanese patients with GIST or
RCC [21, 22] were dose-corrected to 37.5 mg and compared.
Blood samples were obtained at screening, week 5, and
week 9, and then every 8 weeks to assess chromogranin A
(CgA) levels (all patients) and hormone levels (patients with
functional tumors only). Patients were required to fast
for ≥10 h prior to each scheduled visit. In an exploratory
analysis of CgA levels, a biochemical response was defined
as a ≥50 % decrease in CgA levels among patients with
elevated CgA levels at baseline.
Statistical methods
As pancreatic NETs are rare, a target sample size of at least
10 patients was determined based on feasibility of study
conduct rather than statistical requirements. All enrolled
patients who received at least one dose of study treatment
were included in the efficacy and safety analyses.
Descriptive statistics were used to summarize patient
characteristics, treatment administration/compliance, safety
parameters, and PK variables. For the analysis of the prima-
ry endpoint, the CBR and its exact 95 % CI were calculated.
For the analysis of the secondary endpoints, the ORR and its
exact 95 % CI, and the percentage change from baseline in
the sum of the longest diameter of target lesions were
calculated. Time-to-event endpoints (PFS and OS) were
summarized using Kaplan–Meier methods.
Results
Patients and treatment
Between July and December 2010, 12 patients (8 male, 4
female) were enrolled in the study at four centers in Japan.
All patients received treatment and were analyzed for effi-
cacy and safety. At data cut-off (March 2012), treatment was
ongoing in 5 patients with a PR (n04) or SD (n01), and 7
patients had withdrawn from the trial. Study withdrawals
were due to tumor progression or recurrence (n03), with-
drawal of consent (n01), treatment interruption >4 weeks
due to a serious adverse event (SAE; grade 4 enterocolitis;
n01), and SAEs (grade 4 convulsion plus grade 4 loss of
consciousness; n01). Demographic and baseline disease
characteristics are presented in Table 1. All of the patients
had well-differentiated pancreatic NETs, of which 10 were
classified as nonfunctional and 2 as functional (both gastri-
nomas). Six patients had received prior octreotide treatment
and continued octreotide therapy during the study.
The median relative sunitinib dose intensity was 51 %
(range, 26–94); the median number of treatment cycles
started was 16 (range, 3–21; Table 2). The sunitinib dose
was interrupted in 11 patients and reduced in 8 patients. The
most frequently reported cause of dosing interruptions or
reductions was AEs.
Efficacy
Based on investigator assessments, 6 of the 12 patients
experienced a PR, and none had a CR (Fig. 1). SD
≥24 weeks was observed in 3 patients, and the CBR was
75 % (95 % CI, 43–94). In total, 5/6 patients with prior or
concurrent octreotide treatment and 4/6 patients who did not
receive octreotide met the criteria for experiencing clinical
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benefit. The overall ORR was 50 % (95 % CI, 21–79;
Fig. 1). One patient showed a 100 % decrease in target
lesion size. One PR occurred in a patient with gastrinoma
and was accompanied by a 93 % decrease in plasma gastrin
levels (Patient D; Data Supplement Table S1; see also be-
low). In 11/12 patients, some degree of tumor shrinkage was
observed by the first assessment 1 month after initiation of
sunitinib treatment (Fig. 2). At the time of data cut-off,
ongoing patients had been observed for at least 16.1 months,
and the median duration of treatment with sunitinib was
9.8 months (range, 0.7–18.1). Although 4/12 patients had
discontinued treatment with sunitinib due to reasons other
than progressive disease (PD), median PFS had not yet been
reached. Six-month and 12-month PFS probabilities were
91 % (95 % CI, 54–99) and 71 % (95 % CI, 34–90),
respectively. Median OS had not yet been reached. One
death occurred (due to progression of primary disease) dur-
ing survival follow-up, more than 28 days after the end of
treatment.
Safety
As of March 2012, the most common treatment-emergent
(all-causality) AEs of any grade were diarrhea (n010;
83 %), hand–foot syndrome and hypertension (both n08;
67 %); fatigue and headache (both n07; 58 %), and neu-
tropenia (n06; 50 %; Table 3). Grade 3 AEs reported in at
least 2 patients were neutropenia (n06; 50 %) and leukope-
nia (n02; 17 %). Four patients (33 %) experienced grade 4
AEs, all of which were judged to be related to treatment
(herpes encephalitis, convulsion, and loss of consciousness
[n01], increased lipase [n02], and enterocolitis [n01]). No
deaths related to sunitinib treatment were reported on study
or within 28 days of the end of treatment. One death due to
disease progression occurred >28 days after end of
treatment.
Three patients (25 %) experienced SAEs, all of which
resolved. In two cases, the SAEs were assessed as treatment-
related. One patient (patient H; Fig. 2) had a grade 4 con-
vulsion and grade 4 loss of consciousness that were reported
to be likely due to herpes encephalitis. These SAEs resulted
in a sunitinib dose interruption exceeding 4 weeks that led to
study discontinuation, as specified in the protocol. Another
patient (patient K; Fig. 2) experienced an SAE of grade 4
enterocolitis and temporarily discontinued therapy due to
this SAE.
Table 1 Patient characteristics at baseline







ECOG performance status, n (%)
0 11 (92)
1 1 (8)
Time since diagnosis, years
Median 3
Range 0.2–9.0




Number of involved disease sites per patient, n (%)
1 site 4 (33)
2 sites 5 (42)
3 sites 2 (17)
4 sites 1 (8)
Presence of distant metastases, n (%)
Any, including hepatic 12 (100)
Extrahepatic 3 (25)
Involved disease sites, n (%)
Liver 12 (100)





Prior surgery, n (%)
Yes 9 (75)
No 3 (25)
Prior radiation therapy, n (%)
Yes 1 (8)
No 11 (92)





ECOG Eastern cooperative oncology group
Table 2 Sunitinib treatment
Sunitinib (N012)
Treatment cycles started, median (range) 16 (3–21)
Months on treatment, median (range) 10 (0.7–18)
Months on study, median (range) 14 (0.7–19)
No. of patients with ≥1 dosing interruption, n (%) 11 (92)
No. of patients with ≥1 dose reduction, n (%) 8 (67)
Relative dose intensity, median (range), % 51 (26–94)
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Pharmacokinetics
Steady-state concentrations of sunitinib, SU12662, and total
drug (sunitinib plus SU12662) were reached by day 15 of
cycle 1. Subsequent sampling on day 1 of cycles 2–4 showed
the concentrations to be sustained following CDD with suni-
tinib without disproportionate accumulation across cycles
(data not shown). Mean dose-corrected (reference dose:
37.5 mg) Ctrough values were within the ranges of 41.7–
53.9 ng/mL for sunitinib, 19.6–25.7 ng/mL for SU12662,
and 62.9–77.5 ng/mL for total drug.
We explored potential differences in steady-state Ctrough
values of sunitinib and SU12662 in Japanese versus non-
Japanese patient populations and in patients with different
tumor types. Dose-corrected steady-state Ctrough levels from
this Japanese study were compared with findings from a
Western pancreatic NET population [17], and from studies
of Japanese patients with gastrointestinal stromal tumor
(GIST) or renal cell carcinoma (RCC) [21, 22]. Steady-
state Ctrough levels of sunitinib, SU12662, or total drug were
not significantly different between Japanese and primar-
ily Western patients with pancreatic NET, or between




Plasma CgA levels were measured in all 12 patients (Fig. 2).
At baseline, the median CgA concentration was 9 pmol/mL
(range, 3–86 pmol/mL). Six patients had above-median
CgA levels at baseline, 3 of whom had a maximum percent-
age decrease in CgA concentrations of at least −50 %.
Among these 3 patients, 2 had a PR and 1 had a best overall
response of SD. In the patient with SD, the maximum
percentage change in tumor size from baseline was −28 %.
Among the 6 patients with below-median CgA levels, 3
experienced a PR and 3 had a best overall response of
SD. Tumor responses in all 12 patients did not appear
to correlate with the maximum percentage decrease in
CgA levels.
Gastrin
Plasma gastrin levels were assessed in the 2 patients with
gastrinomas: a 40-year-old female (patient D) and a 34-year-
old male (patient L; Data Supplement Table S1). In addition,
the relationship between hormonal levels, tumor size, and
objective tumor response (based on investigator assessment)
was examined in an exploratory analysis. In the male pa-
tient, neither gastrin levels nor tumor size decreased after
treatment with sunitinib. The best objective response was
PD, and the patient discontinued the study at day 79 due to
lack of efficacy. In the female patient with gastrinoma,
decreases in both gastrin levels (−85 % to −93 %) and tumor
size (−31 % to −45 %) were observed during treatment. This
patient had a PR on cycle 2 day 1 that was maintained
through cycle 7 day 1.
Discussion
This is the first report of sunitinib safety, PK profiles, PFS,
and antitumor activity in Japanese patients with unresect-
able, advanced/metastatic well-differentiated pancreatic
NET. While the data are limited by the small sample size,
antitumor activity was observed in this population, with a
CBR of 75 % and an ORR of 50 %. The ORR was encour-
aging and higher than the 9 % ORR reported for sunitinib in
a randomized, phase III trial in a predominantly non-Asian
population [7]. In the present study, 11 patients had
Fig. 1 Maximum percentage
reduction from baseline in
target lesion size by patient (N0
12). Although one patient had a
maximum percentage change in
target tumor size from baseline
of −100 %, non-target lesions
remained and therefore this was
not classified as a complete re-
sponse. Asterisk stable disease
of ≥24 weeks in duration;
RECIST Response Evaluation
Criteria in Solid Tumors
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decreases in target lesion measurements and achieved a best
response of a PR or SD. Analysis of the percentage change
in target lesion size over time showed a trend in tumor
shrinkage from the first assessment 1 month after initiation
of treatment with sunitinib. As of March 2012, ongoing
patients had been observed for at least 16.1 months, and
median PFS had not been reached. The probability of being
alive and progression-free at 6 months was 91 % (95 % CI,
54–99) and at 12 months was 71 % (95 % CI, 34–90). In the
randomized sunitinib phase III trial, median PFS was
11.4 months [7]. These data suggest that PFS in
Japanese patients receiving sunitinib in our study may
be equivalent to or greater than that observed in the
randomized phase III trial.
The potential effect of octreotide therapy was difficult to
evaluate in this study due to the small sample size. The CBR
was similar among patients with (n05/6) or without (n04/6)
octreotide treatment. In an exploratory subpopulation anal-
ysis reported in the randomized sunitinib phase III study, the
efficacy of sunitinib appeared similar in patients who did
and did not receive somatostatin analogues (PFS hazard
ratios of 0.43 and 0.41, respectively), suggesting that the
efficacy of sunitinib was not affected by somatostatin ana-
logue treatment [7].
AEs reported during sunitinib treatment were man-
ageable with palliative care measures, such as dosing
interruption. The AEs observed in this study were sim-
ilar to those reported in a phase III study in primarily
Western patients with pancreatic NET [7], and frequent-
ly observed AEs were comparable to those reported in
patients with GIST or RCC [21, 22].
In the current study, the median number of treatment
cycles started was 16. All patients had grade 3/4 AEs and
at least one sunitinib dosing interruption. However, the
therapeutic effect of sunitinib did not appear to be reduced
by temporary dosing interruptions due to AEs. Neutropenia,
the most common grade 3/4 AE, was also the most frequent-
ly reported grade 3/4 toxicity in the predominantly Western
sunitinib phase III pancreatic NET study [7], although the
frequency of this event was markedly higher in our study
with Japanese patients (42 % vs. 12 %). Increased rates of
grade 3/4 neutropenia have also been observed in sunitinib-
treated Japanese patients with GIST (37 % vs. 10 %) or
RCC (53 % vs. 18 %), compared with predominantly
Western populations [21–24]. The frequency of grade 3/4
thrombocytopenia similarly appeared to be higher in
sunitinib-treated Japanese vs. Western patients (GIST:
20 % vs. 4 %; RCC: 55 % vs. 9 %; pancreatic NET:
Table 3 Treatment-emergent
(all-causality) adverse events
(AEs) reported in ≥25 % of
patients, according to the Na-
tional Cancer Institute Common
Terminology Criteria for Ad-
verse Events version 4.0
aGrade 4 AEs were observed in 4
patients: convulsion, loss of
consciousness, and herpes en-
cephalitis (n01), increased li-
pase (n02), and enterocolitis
(n01); no grade 5 AEs were
reported
bPatients were counted once,
with only the highest grade AE
listed
Maximum grade (G), n (%)
AE G1 G2 G3 Totala
Any AEb 0 0 8 12 (100)
Diarrhea 4 (33) 5 (42) 1 (8) 10 (83)
Hand–foot syndrome 1 (8) 7 (58) 0 8 (67)
Hypertension 1 (8) 7 (58) 0 8 (67)
Fatigue 1 (8) 6 (50) 0 7 (58)
Headache 4 (33) 3 (25) 0 7 (58)
Neutropenia 0 0 6 (50) 6 (50)
Dysgeusia 5 (42) 0 0 5 (42)
Nasopharyngitis 4 (33) 1 (8) 0 5 (42)
Nausea 4 (33) 1 (8) 0 5 (42)
Pyrexia 2 (17) 2 (17) 1 (8) 5 (42)
Vomiting 5 (42) 0 0 5 (42)
Decreased appetite 4 (33) 0 0 4 (33)
Edema 3 (25) 1 (8) 0 4 (33)
Hypothyroidism 0 4 (33) 0 4 (33)
Leukopenia 0 1 (8) 2 (17) 3 (25)
Mucosal inflammation 2 (17) 1 (8) 0 3 (25)
Muscle spasms 3 (25) 0 0 3 (25)
Prolonged electrocardiogram QT 1 (8) 1 (8) 1 (8) 3 (25)
Thrombocytopenia 1 (8) 1 (8) 1 (8) 3 (25)
Fig. 2 Individual patient profiles and response to treatment (N012). a
Summary of patient profiles and changes in tumor-size and chromog-
ranin A levels. b Percentage change from baseline in target lesion size
over time in individual patients. a Maximum % change 0 [(minimum
value after dosing – baseline)/baseline] x 100; b Based on censored
data; F female; M male; PD progressive disease; PFS progression-free
survival; PR partial response; SD stable disease
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17 % vs. 4 %) [21–24]. It should be noted that the
sunitinib GIST and RCC trials used a different dosing
schedule (sunitinib 50 mg/day, for 4 weeks on therapy,
followed by 2 weeks off) than our study and the phase
III, pancreatic NET trial.
It is not clear why rates of grade 3/4 hematologic AEs
appear to be higher in Japanese versus Western patients who
receive sunitinib. Analysis of PK parameters has shown that
the area under the concentration–time values of sunitinib
and SU12662 are similar in Japanese and Caucasian patients
with RCC [22]. In addition, when steady-state Ctrough values
from this Japanese study were compared with those from a
Western pancreatic NET population [17] and with Ctrough
values from Japanese patients with GIST or RCC [21, 22],
there were no significant differences in the dose-corrected
Ctrough levels of sunitinib, SU12662, or total drug between
Japanese and primarily Western patients with pancreatic
NET, or among patients with pancreatic NET, GIST, or
RCC. In the absence of racial or ethnic differences in the
PK of sunitinib, Uemura et al. [25] suggested that the
elevated rates of grade 3/4 hematologic AEs in Japanese
patients may be due to differences in the expression levels
and activity of sunitinib-sensitive kinases involved in the
regulation of hematopoiesis.
Everolimus, an inhibitor of the mammalian target of
rapamycin, is approved for the treatment of pancreatic
NET in Japan, and like sunitinib is commonly associated
with skin and gastrointestinal disorders [9]. Additional AEs
related to sunitinib treatment include hematotoxicity, cardio-
vascular disorders and constitutional symptoms [26], while
pneumonitis and infections are associated with everolimus
therapy [27]. These different safety profiles reflect each
compound’s distinct mode of action. No racial differences
between Japanese and Western patients have been reported
for the safety profile of either drug, based on the current
study and a subgroup analysis of Japanese patients in the
RADIANT-3 everolimus trial [9].
Treatment-emergent changes in CgA levels may pro-
vide a means to select patients with pancreatic NET
likely to benefit from molecular targeted therapy [28].
However, in this study tumor responses in all 12
patients did not appear to correlate with the maximum
percentage decrease in CgA levels, possibly because of
small patient numbers with elevated CgA concentrations
at baseline. Patient D had the highest baseline CgA
levels in the study (86 pmol/mL), and decreased CgA
concentrations (−89 %) were subsequently observed in
combination with a PR. An increase in CgA levels
(300 %) occurred during the study in 1 patient
(Patient L) who experienced PD. A potential correlation
between changes in CgA levels and clinical benefit was
considered in these 2 patients. In patients with elevated
baseline CgA concentrations, CgA appeared to be a
useful marker in patients with pancreatic NET as
reported previously [29].
The use of sunitinib marks a new phase in the develop-
ment of a more targeted approach to the treatment of
advanced-stage pancreatic NET. Results from the current
study demonstrate antitumor activity in Japanese
patients with unresectable, well-differentiated pancreatic
NET and corroborate earlier findings in Western and
Asian populations.
Fig. 3 Trough concentrations of sunitinib, active metabolite SU12662,
and total drug (sunitinib plus SU12662) in Japanese patients with
pancreatic neuroendocrine tumor (NET; n011; present study) or gas-
trointestinal stromal tumor (GIST; n030) [21] and renal cell carcinoma
(RCC; n038; pooled data) [25], and in predominantly Western patients
with pancreatic NET; n057 [17]. The sunitinib dose in each study was
dose-corrected to 37.5 mg. The upper and lower box boundaries
denote the 75th and 25th percentiles, respectively, with the median
shown as a line within the box. Whiskers indicate minimum and
maximum values. Outlying values are denoted as circles
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